Effect of lentiviral vector‑packaged interleukin‑18 gene on the malignant behavior of lung cancer

Chen,Xiangqi; Feng,Rui; Xiong,Donglan; Yang,Sheng; Lin,Tingyan

doi:10.3892/etm.2019.8204

Effect of lentiviral vector‑packaged interleukin‑18 gene on the malignant behavior of lung cancer

Authors:
- Xiangqi Chen
- Rui Feng
- Donglan Xiong
- Sheng Yang
- Tingyan Lin
View Affiliations

Affiliations: Teaching and Research Department of Respiratory Medicine, Union Clinical Medical College of Fujian Medical University, Fuzhou, Fujian 350001, P.R. China, Department of Oncology Medicine, Fujian Medical University Union Hospital, Fuzhou, Fujian 350001, P.R. China
Published online on: November 15, 2019 https://doi.org/10.3892/etm.2019.8204
Pages: 319-326

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Interleukin‑18 (IL‑18) is a multifunctional cytokine that exhibits antitumor, anti‑infection and immunoregulatory functions. This study aimed to investigate the effects of lentiviral vector‑packaged interleukin (IL)‑18 gene on the malignant behavior of lung cancer and the potential underlying molecular mechanism of IL‑18 anticancer activity. Human lung adenocarcinoma A549 cells transfected with human IL‑18 gene‑containing lentiviral expression vector were the IL‑18 intervention group (group A), cells transfected with the empty lentiviral expression vector were empty vector group (group B), and cells without any intervention were the blank control group (group C). Reverse transcription‑quantitative PCR and western blotting were used to determine IL‑18 mRNA and protein expression levels. Cell Counting Kit‑8, colony‑formation, flow cytometry, invasion and wound‑healing assays were used to evaluate the malignant behavior of A549 cells transfected with the IL‑18 lentiviral vector. The expression levels of the T helper (Th)1 cell cytokine interferon‑γ (IFN‑γ) and the Th2 cell cytokine IL‑4 were tested by ELISA, and western blotting was used to test the expressing of nuclear factor κB (NF‑κB). The results demonstrated that IL‑18 mRNA and protein expression levels in group A were significantly increased compared with groups B and C; the expression levels of IFN‑γ in group A were higher and the expression levels of IL‑4 in group A were lower compared with those in groups B and C; and the expression of NF‑κB was increased in the cytoplasm and decreased in the nucleus in group A compared with groups B and C. The data indicated that, compared with the control groups, the IL‑18 gene lentiviral expression vector increased the expression of IL‑18, diminished A549 cell proliferative ability, enhanced apoptosis, decreased the invasive and metastatic capacities of the cells, promoted the secretion of IFN‑γ, decreased the production of IL‑4, reversed the imbalance of Th1/Th2 cell subsets and inhibited the nuclear activation of NF‑κB, which collectively present an anti‑lung cancer mechanism and deserve further study.

View Figures

View References

1	Schild SE and Vokes EE: Pathways to improving combined modality therapy for stage III nonsmall-cell lung cancer. Ann Oncol. 27:590–599. 2016. View Article : Google Scholar : PubMed/NCBI
2	Fiala O, Šorejs O, Pešek M and Fínek J: Immunotherapy in the treatment of lung cancer. Klin Onkol. 30 (Supplementum3):22–31. 2017.(In Czech). View Article : Google Scholar : PubMed/NCBI
3	Hontscha C, Borck Y, Zhou H, Messmer D and Schmidt-Wolf IG: Clinical trials on CIK cells: First report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol. 137:305–310. 2011. View Article : Google Scholar : PubMed/NCBI
4	Dougan M and Dranoff G: Immune therapy for cancer. Annu Rev Immunol. 27:83–117. 2009. View Article : Google Scholar : PubMed/NCBI
5	Li R, Wang C, Liu L, Du C, Cao S, Yu J, Wang SE, Hao X, Ren X and Li H: Autologous cytokine-induced killer cell immunotherapy in lung cancer: A phase II clinical study. Cancer Immunol Immunother. 61:2125–2133. 2012. View Article : Google Scholar : PubMed/NCBI
6	Tian H, Shi G, Yang G, Zhang J, Li Y, Du T, Wang J, Xu F, Cheng L, Zhang X, et al: Cellular immunotherapy using irradiated lung cancer cell vaccine co-expressing GM-CSF and IL-18 can induce significant antitumor effects. BMC Cancer. 14:482014. View Article : Google Scholar : PubMed/NCBI
7	Tse BW, Russell PJ, Lochner M, Förster I and Power CA: IL-18 inhibits growth of murine orthotopic prostate carcinomas via both adaptive and innate immune mechanisms. PLoS One. 6:e242412011. View Article : Google Scholar : PubMed/NCBI
8	Zheng JN, Pei DS, Mao LJ, Liu XY, Sun FH, Zhang BF, Liu YQ, Liu JJ, Li W and Han D: Oncolytic adenovirus expressing interleukin-18 induces significant antitumor effects against melanoma in mice through inhibition of angiogenesis. Cancer Gene Ther. 17:28–36. 2010. View Article : Google Scholar : PubMed/NCBI
9	Jia Y, Zang A, Jiao S, Chen S and Yan F: The interleukin-18 gene promoter-607 A/C polymorphism contributes to non-small-cell lung cancer risk in a Chinese population. Onco Targets Ther. 9:1715–1719. 2016. View Article : Google Scholar : PubMed/NCBI
10	Timperi E, Focaccetti C, Gallerano D, Panetta M, Spada S, Gallo E, Visca P, Venuta F, Diso D, Prelaj A, et al: IL-18 receptor marks functional CD8+ T cells in non-small cell lung cancer. Oncoimmunology. 6:e13283372017. View Article : Google Scholar : PubMed/NCBI
11	Senju H, Kumagai A, Nakamura Y, Yamaguchi H, Nakatomi K, Fukami S, Shiraishi K, Harada Y, Nakamura M, Okamura H, et al: Effect of IL-18 on the expansion and phenotype of human natural killer cells: Application to cancer immunotherapy. Int J Biol Sci. 14:331–340. 2018. View Article : Google Scholar : PubMed/NCBI
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
13	Yoshimitsu M, Sato T, Tao K, Walia JS, Rasaiah VI, Sleep GT, Murray GJ, Poeppl AG, Underwood J, West L, et al: Bioluminescent imaging of a marking transgene and correction of Fabry mice by neonatal injection of recombinant lentiviral vectors. Proc Natl Acad Sci USA. 101:16909–16914. 2004. View Article : Google Scholar : PubMed/NCBI
14	Yamamura M, Modlin RL, Ohmen JD and Moy RL: Local expression of antiinflammatory cytokines in cancer. J Clin Invest. 91:1005–1010. 1993. View Article : Google Scholar : PubMed/NCBI
15	Asselin S, Conjeaud H, Minty A, Fradelizi D and Breban M: Stable polarization of peripheral blood T cells towards type 1 or type 2 phenotype after polyclonal activation. Eur J Immunol. 28:532–539. 1998. View Article : Google Scholar : PubMed/NCBI
16	Chechlińska M, Duma A, Swierkowska K, Kamińska J and Steffen J: Sera of lung cancer patients affect the release of Th1, Th2 and monocyte-derived cytokines, and the expression of IL-2Ralpha by normal, stimulated mononuclear cells. Cell Mol Biol Lett. 9:69–81. 2004.PubMed/NCBI
17	Yamashita K, Iwasaki T, Tsujimura T, Sugihara A, Yamada N, Ueda H, Okamura H, Futani H, Maruo S and Terada N: Interleukin-18 inhibits lodging and subsequent growth of human multiple myeloma cells in the bone marrow. Oncol Rep. 9:1237–1244. 2002.PubMed/NCBI
18	Yamanaka R and Xanthopoulos KG: Induction of antigen-specific immune responses against malignant brain tumors by intramuscular injection of sindbis DNA encoding gp100 and IL-18. DNA Cell Biol. 24:317–324. 2005. View Article : Google Scholar : PubMed/NCBI
19	Park S, Cheon S and Cho D: The dual effects of interleukin-18 in tumor progression. Cell Mol Immunol. 4:329–335. 2007.PubMed/NCBI
20	Nakamura Y, Yamada N, Ohyama H, Nakasho K, Nishizawa Y, Okamoto T, Futani H, Yoshiya S, Okamura H and Terada N: Effect of interleukin-18 on metastasis of mouse osteosarcoma cells. Cancer Immunol Immunother. 55:1151–1158. 2006. View Article : Google Scholar : PubMed/NCBI
21	Xu T, Hao XS, Ren XB and Zhang HL: Killing effect of interleukin-18-enhanced FasL-expressing colon cancer cells on human hepatocytes in vitro. Zhonghua Zhong Liu Za Zhi. 32:659–662. 2010.(In Chinese). PubMed/NCBI
22	Napetschnig J and Wu H: Molecular basis of NF-κB signaling. Annu Rev Biophys. 42:443–468. 2013. View Article : Google Scholar : PubMed/NCBI
23	Karin M: Nuclear factor-kappaB in cancer development and progression. Nature. 441:431–436. 2006. View Article : Google Scholar : PubMed/NCBI
24	Slattery ML, Mullany LE, Sakoda L, Samowitz WS, Wolff RK, Stevens JR and Herrick JS: The NF-κB signalling pathway in colorectal cancer: Associations between dysregulated gene and miRNA expression. J Cancer Res Clin Oncol. 144:269–283. 2018. View Article : Google Scholar : PubMed/NCBI
25	Yang L, Zhou Y, Li Y, Zhou J, Wu Y, Cui Y, Yang G and Hong Y: Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells. Cancer Lett. 357:520–526. 2015. View Article : Google Scholar : PubMed/NCBI
26	Zeng Q, Li S, Zhou Y, Ou W, Cai X, Zhang L, Huang W, Huang L and Wang Q: Interleukin-32 contributes to invasion and metastasis of primary lung adenocarcinoma via NF-kappaB induced matrix metalloproteinases 2 and 9 expression. Cytokine. 65:24–32. 2014. View Article : Google Scholar : PubMed/NCBI
27	Zhang H, Zhang Z and Xu Y: Effects of interleukin-18 on asthmatic airway inflammation and nuclear factor kappa-B in murine models. Chin Med J (Engl). 116:323–327. 2003.PubMed/NCBI
28	Kanda N, Shimizu T, Tada Y and Watanabe S: IL-18 enhances IFN-gamma-induced production of CXCL9, CXCL10, and CXCL11 in human keratinocytes. Eur J Immunol. 37:338–350. 2007. View Article : Google Scholar : PubMed/NCBI
29	Robertson MJ, Kirkwood JM, Logan TF, Koch KM, Kathman S, Kirby LC, Bell WN, Thurmond LM, Weisenbach J and Dar MM: A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer. Clin Cancer Res. 14:3462–3469. 2008. View Article : Google Scholar : PubMed/NCBI
30	Tarhini AA, Millward M, Mainwaring P, Kefford R, Logan T, Pavlick A, Kathman SJ, Laubscher KH, Dar MM and Kirkwood JM: A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma. Cancer. 115:859–868. 2009. View Article : Google Scholar : PubMed/NCBI